TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ — Panaxia Global, the controlling owner of Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), Israel’s largest manufacturer of medical cannabis products, and its partner, Neuraxpharm, Europe’s leading pharmaceutical company specialized in the central nervous system (CNS) today announced that they are expanding their strategic collaboration into the French market and that they have signed a binding memorandum of understanding between Panaxia and subsidiary Neuraxpharm France for the manufacture, commercialization and distribution of Panaxia’s advanced medical cannabis products in France, including exclusivity for Panaxia’s products.
The commercial collaboration between the parties is based on a model much like that in Germany: Panaxia will be responsible for manufacturing the products it has developed at strict clinically-backed standards, such as…